Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Amyotrophic Lateral Sclerosis (ALS): Motor Neuron Failure and Cellular Defense

A neurodegenerative pathogenesis brief on the two-tier motor circuit, TDP-43 mislocalization, glutamate excitotoxicity, mitochondrial and axonal transport failure, onset patterns and current therapies.

Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026

Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.

What we found that needs correcting

  • Creatine is recommended for ATP buffering. It has been tested in several randomized trials in ALS and did not slow progression or improve survival. This is not an absence of evidence; it is a negative result from real trials, and the brief should not recommend it.
  • Coenzyme Q10 was tested in ALS at high dose and did not show benefit sufficient to justify a larger trial. The same applies.
  • High-dose methylcobalamin is the one supplement in the table with supportive evidence, and the brief undersells rather than oversells it. A Japanese trial in people early in the disease showed a modest slowing of functional decline, and it was approved for ALS in Japan in 2024. It is not approved elsewhere, and the benefit was in a selected group treated early.
  • Vitamin D, omega-3 fats and curcumin have no trial evidence of benefit in ALS. The mechanisms given are plausible and untested. In a disease where people are vulnerable to unproven treatments, the distinction between mechanism and evidence should be explicit.
  • The high-calorie nutrition section is the strongest part of the brief and deserves more emphasis than the supplements beside it. Hypermetabolism and weight loss as a predictor of faster progression are well supported, and high-calorie feeding has trial support. This is one of the rare areas in ALS where nutrition advice is as well evidenced as the drugs.
  • Relyvrio (AMX0035) is absent. It was approved in the US and Canada and then withdrawn in 2024 after a larger trial showed no benefit. People reading older material still ask about it, and the brief should say what happened.
  • Tofersen's status is overstated. Its main trial did not meet its primary clinical endpoint; it was approved under accelerated approval on the strength of neurofilament reduction, with confirmatory evidence still accruing. It applies to roughly 2 percent of cases.
  • Edaravone is presented without geography. It is approved in the US and some other countries; the European Medicines Agency declined approval, judging the evidence insufficient. A reader in Europe should know why their neurologist may not offer it.
  • Riluzole's effect size is not given. In trials it extended survival by roughly two to three months on average. Stating that plainly respects the reader's ability to weigh it, and most people still choose to take it.
  • The FTD overlap figure of about 15 percent is correct for people meeting full criteria for frontotemporal dementia, and it understates the broader picture: around half of people with ALS have some degree of cognitive or behavioural change on detailed testing, typically in executive function, language and behaviour rather than memory. Families benefit from knowing this.
  • Sensation is described as remaining intact. That is broadly true and slightly absolute. Sensory abnormalities occur in a minority, and pain, mostly musculoskeletal and from immobility, is common and treatable. People are sometimes told ALS is painless and then not offered pain relief.
  • There is nothing on diagnosis or on the conditions that mimic ALS, and that is the most consequential gap. Multifocal motor neuropathy with conduction block, cervical spondylotic myelopathy, myasthenia gravis and Kennedy's disease can all resemble ALS, and several of them are treatable. A brief on ALS pathogenesis that never mentions this leaves out the thing that most changes an individual outcome.
  • Symptomatic treatment is missing entirely: cramps, spasticity, sialorrhoea, thick secretions, pain, poor sleep and pseudobulbar affect are all common and all treatable, and are routinely under-reported by patients because they assume they are simply part of the disease.
  • The brief does not mention that veterans have higher rates of ALS and that in the US it is recognized as a presumptive service-connected condition. That is a practical fact that affects access to care and benefits and is frequently missed.
  • Gastrostomy timing deserves more than a mention in passing: placement is safer before respiratory function declines, which is why it is discussed earlier than people expect.
  • The core neuroscience is accurate and clearly explained: the two-tier upper and lower motor neuron circuit and the distinct signs each produces, dying-back degeneration beginning at the neuromuscular junction, TDP-43 mislocalization and aggregation in the great majority of cases, impaired glutamate clearance by astrocytes through EAAT2, mitochondrial failure and oxidative stress in a cell with exceptional energy demands, axonal transport breakdown, the shift of microglia from support to inflammation, the limb and bulbar onset patterns with their proportions, the respiratory milestone, and the sparing of extraocular muscles, sphincters and sensation.

Download the PDF

All source documents